ASCO 2024

 
Virtual Simulcast
 
In-Person
 
Free CME Credits

Free Oncology Symposia in Conjunction With the 2024 ASCO Annual Meeting

Discover the latest breakthroughs in oncology and hematology in June, held both in Chicago and virtually. Join expert faculty for exciting satellite symposia, where you will interact with other professionals and receive practical guidance on a wide range of malignancies.

The best part? You do not need to be an ASCO registrant to join our events! Claim free CME/CE credits and receive complimentary slides to support your presentation needs.

 

Dates May 31st - June 2nd

 

Time Varies per Event
Timezone Converter ›

 

Location Hilton Chicago
720 S. Michigan Ave.
Chicago, IL 60605

 

Bus Route Coming Soon

Event Schedule

Attend in-person or via virtual simulcast.

May

31

2024

6:30 PM - 8:30 PM Central Time (CT)

In-person

7:00 PM - 8:30 PM Central Time (CT)

Virtual

June

01

2024

June

01

2024

6:30 PM - 8:30 PM Central Time (CT)

In-person

7:00 PM - 8:30 PM Central Time (CT)

Virtual

Featured Faculty

Faculty

Jeremy S. Abramson, MD, MMSc

  • Professor
  • Department of Medicine
  • Division of Hematology/ Oncology
  • Geffen School of Medicine at UCLA
  • Los Angeles, California
Faculty

Jaffer A. Ajani, MD

  • Professor, Department of Gastrointestinal Medical Oncology
  • The University of Texas MD Anderson Cancer Center
  • Houston, Texas
Faculty

Farrukh Awan, MD

  • Professor of Internal Medicine
  • Director of Lymphoid Malignancies Program
  • Harold C. Simmons Comprehensive Cancer Center
  • University of Texas Southwestern Medical Center
  • Dallas, Texas
Faculty

Aditya Bardia, MD, MPH

  • Director, Breast Cancer Research
  • Associate Professor
  • Harvard Medical School
  • Attending Physician
  • Massachusetts General Hospital
  • Boston, Massachusetts
Faculty

Mitesh J. Borad, MD

  • Professor of Medicine
  • Mayo Clinic College of Medicine and Science
  • Phoenix, Arizona
Faculty

Richard S. Finn, MD

  • Director, Center for Lymphoma
  • Massachusetts General Hospital
  • Associate Professor of Medicine
  • Harvard Medical School
  • Boston, Massachusetts
Faculty

Lipika Goyal, MD, MPhil

  • Associate Professor in Medicine
  • Director of Gastrointestinal Oncology
  • Associate Professor of Medicine
  • Stanford School of Medicine
  • Palo Alto, California
Faculty

James J. Harding, MD

Faculty

Sara A. Hurvitz, MD, FACP

  • Professor of Medicine
  • Head
  • Division of Hematology and Oncology
  • Department of Medicine
  • UW Medicine
  • Senior Vice President
  • Clinical Research Division Fred Hutchinson Cancer Center
  • Seattle, Washington
Faculty

Natasha Leighl, MD, MMSC, FRCPC, FASCO

  • Lung Site Lead, Medical Oncology
  • OSI Pharmaceuticals Foundation Chair
  • Princess Margaret Cancer Centre
  • Professor of Medicine, University of Toronto
  • Toronto, Canada
Faculty

Shuo Ma, MD, PhD

  • Professor of Medicine
  • Division of Hematology-Oncology
  • Department of Medicine
  • Robert H. Lurie Comprehensive Cancer Center
  • Northwestern University Feinberg School of Medicine
  • Chicago, Illinois
Faculty

Cynthia Nguyen, PharmD, BCIDP

  • Clinical Pharmacy Specialist, Infectious Diseases
  • University of Chicago Medicine
  • Chicago, Illinois
Faculty

Joyce O'Shaughnessy, MD

  • Celebrating Women Chair in Breast Cancer Research
  • Baylor University Medical Center
  • Chair, Breast Disease Committee
  • Texas Oncology Sarah Cannon Research Institute
  • Dallas, Texas
Faculty

Karen Reckamp, MD, MS

  • Professor in Medicine
  • Director, Division of Medical Oncology
  • Associate Director, Clinical Research
  • Cedars-Sinai Medical Center
  • Los Angeles, California
Faculty

Mazyar Shadman, MD, MPH

  • Innovators Network Endowed Chair
  • Associate Professor of Hematology and Oncology
  • Lymphoid Malignancies and Immunotherapy
  • Fred Hutch Cancer Center and University of Washington
  • Seattle, Washington
Faculty

Shmuel Shoham, MD

  • Professor of Clinical Medicine
  • Transplant and Oncology Infectious Diseases Program
  • Johns Hopkins University School of Medicine
  • Baltimore, Maryland
Faculty

Maximilian Stahl, MD

  • Department of Medical Oncology
  • Dana-Farber Cancer Institute
  • Harvard Medical School
  • Boston, Massachusetts
Faculty

Nataliya Uboha, MD, PhD

  • Associate Professor
  • Hematology/Oncology
  • University of Wisconsin, Carbone Cancer Center
  • Madison, Wisconsin
Faculty

Zev A. Wainberg, MD

  • Co-Director, GI Oncology Program
  • Professor of Medicine and Surgery
  • Director, Early Phase Therapeutics
  • Jonsson Comprehensive Cancer Center
  • UCLA School of Medicine
  • Los Angeles, California
Faculty

Sarah B. White, MD, MS, FSIR

  • Associate Dean, Vice Chair, Professor
  • Department of Radiology
  • Division of Vascular and Interventional Radiology
  • Medical College of Wisconsin
  • Milwaukee, Wisconsin
Faculty

Mark Yarchoan, MD

  • Associate Professor of Medical Oncology
  • Division of GI Malignancies
  • Sidney Kimmel Comprehensive Cancer Center
  • Johns Hopkins University
  • Baltimore, Maryland
Faculty

Amer Zeidan, MBBS, MPH

  • Associate Professor of Medicine (Hematology)
  • Chief, Division of Hematologic Malignancies
  • Yale Comprehensive Cancer Center and Smilow Cancer Hospital
  • New Haven, Connecticut

Accreditation

Caring for Patients With Cancer in a Post-COVID World: Expert Guidance on the Latest Data and Therapeutic Advances to Mitigate Infection Risk
Physicians: maximum of 1.50 AMA PRA Category 1 Credits™
Pharmacists: 1.50 contact hours (0.15 CEUs)
Registered Nurses: 1.50 Nursing contact hours
Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Myelofibrosis Expert Roundtable: State-of-the-Art Clinical Advances and Therapeutic Strategies From JAK Inhibition into the Future
Physicians: maximum of 1.50 AMA PRA Category 1 Credits™

Immunotherapy in HCC: Improving Outcomes Across the Disease Continuum
Physicians: maximum of 1.50 AMA PRA Category 1 Credits™

Redefining the Possibilities for Patients With HER2-Positive Gastroesophageal Cancers
Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Expert Perspectives on the Evolving Treatment of EGFR-Mutated Advanced and Metastatic NSCLC
Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Cancer Conversations on the Expanding Therapeutic Landscape for CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer
Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points
Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Targeted Therapies in Advanced Biliary Tract Cancer: Practical Strategies in a Changing Therapeutic Landscape
Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points
Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Applying NCCN Guidelines for the Treatment of CLL/SLL in Clinical Practice: The Right Agent for the Right Patient at the Right Time
Physicians: maximum of 1.50 AMA PRA Category 1 Credits™
Pharmacists: 1.50 contact hours (0.15 CEUs)
Registered Nurses: 1.50 Nursing contact hours

Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs
Physicians ABIM MOC: maximum of 1.50 Medical Knowledge MOC points
Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Individualizing Therapy in Low-Risk MDS: New Evidence and Options for Your Patients
Physicians: maximum of 1.00 AMA PRA Category 1 Credit™

Hilton Chicago

720 S Michigan Ave
Chicago, IL 60605
Chicago ASCO 2023

Check out our enduring content from previous ASCO conferences

View 2023 Content

Caring for Patients with Cancer in a Post-COVID World: Expert Guidance on the Latest Data and Therapeutic Advances to Mitigate Infection Risk
Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
Supported by an educational grant from AstraZeneca.

Myelofibrosis Expert Roundtable: State-of-the-Art Clinical Advances and Therapeutic Strategies From JAK Inhibition into the Future
Provided by Clinical Care Options, LLC
Supported by an educational grant from GlaxoSmithKline.

Immunotherapy in HCC: Improving Outcomes Across the Disease Continuum
Provided by Clinical Care Options, LLC
Supported by an educational grant from AstraZeneca.

Cancer Conversations on the Expanding Therapeutic Landscape for CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer
Provided by Clinical Care Options, LLC
Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Redefining the Possibilities for Patients With HER2-Positive Gastroesophageal Cancers
Provided by Clinical Care Options, LLC
Supported by an educational grant from AstraZeneca.

Expert Perspectives on the Evolving Treatment of EGFR-Mutated Advanced and Metastatic NSCLC
Provided by Clinical Care Options, LLC
Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

Targeted Therapies in Advanced Biliary Tract Cancer: Practical Strategies in a Changing Therapeutic Landscape
Provided by Clinical Care Options, LLC
Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.

Applying NCCN Guidelines for the treatment of CLL/SLL in Clinical Practice: The Right Agent for the Right Patient at the Right Time
Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
Supported by educational grants from BeiGene; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly. Supported by an independent medical education grant from AbbVie.

Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs
Provided by Clinical Care Options, LLC
Supported by an educational grant from Lilly.

Individualizing Therapy in Low-Risk MDS: New Evidence and Options for Your Patients
Provided by Clinical Care Options, LLC
Supported by an educational grant from Bristol Myers Squibb.

ASCO Disclaimer:
Not an official event of the 2024 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, CancerLinQ®, or Conquer Cancer®,
the ASCO Foundation.